Neuralstem, Inc. news

   Watch this stock
Showing stories 11 - 20 of about 78   

Articles published

CUR 1.70 -0.08 (-4.49%)
price chart
Neuralstem, Inc. – Product Pipeline Market Review – 2014: Radiant Insights, Inc
This report provides comprehensive information on the current therapeutic developmental pipeline of Neuralstem, Inc.
Stock Update (NYSE MKT:CUR): Neuralstem, Inc. Reports First Quarter 2015 ...
Neuralstem, Inc. (NYSE MKT:CUR) a biopharmaceutical company using neural stem cell technology to develop small molecule and cell therapy treatments for central nervous system diseases, reported its financial results for the three months ended March 31, ...
Neuralstem Reports First Quarter 2015 Financial Results And Provides ...  PR Newswire (press release)
An Expert's Opinion On Neuralstem's Phase 2 Results (CUR)
The phase 2a results of Neuralstem's (NASDAQ:CUR) NSI-566 have raised a battle. Good or bad, the results attracted a great deal of attention.
Brean Capital Reiterates Buy on Neuralstem, Inc. Following 4Q:14 Update
Brean Capital's healthcare analyst Jonathan Aschoff weighed in today with a few insights on Neuralstem, Inc. (NYSE MKT:CUR), after the company released its fourth-quarter results and provided an update on its pipeline.
How Successful Was The Neuralstem Phase II Trial?  Seeking Alpha (registration)
Neuralstem Reports Fiscal 2014 Fourth Quarter Financial And Year-End ...  PR Newswire (press release)
Brean Capital Maintains Buy On Neuralstem, Inc. Following KOL Event
In a research report released this morning, Brean Capital analyst Jonathan Aschoff reiterated a Buy rating on Neuralstem, Inc. (NYSE MKT:CUR) with an $8.00 price target, following the company's Key Opinion Leaders (KOL) event, featuring Harvard ...
Neuralstem Inc (CUR) Jumps 5.14% on July 15
Neuralstem Inc (CUR) was among the biggest gainers on the Russell 2000 for Wednesday July 15 as the stock popped 5.14% to $1.84, representing a gain of $0.09 per share.
Investors Dumping 3 Biotech Stocks - Neuralstem, Inc. (NYSEMKT:CUR ...
Neuralstem, Inc. (NYSEMKT:CUR) declined -11.88% to end last trading session at $1.78. The company, on June 29, 2015, released that it has been approved for listing on the NASDAQ Capital Market under the symbol “CUR.
Biotech Decliners: Sarepta Therapeutics, Inc. (NASDAQ:SRPT), Neuralstem, Inc ...  Stock Transcript
DRRX, CUR, CPRX, SRPT, MCRB  Wsnews4investors (press release) (blog)
Company Shares of Neuralstem, Inc. Rally 7.1%
Shares of Neuralstem, Inc. (NYSEMKT:CUR) appreciated by 7.1% during the past week but lost 4.74% on a 4-week basis. The shares have outperformed the S&P 500 by 4.58% in the past week but underperformed the index by 5.48% in the last 4 weeks.
Neuralstem, Inc. (CUR), Bridgepoint Education, Inc. (BPI), Lee Enterprises ...
Neuralstem, Inc. (CUR) of the Healthcare sector finished sub average at the closing bell Fri with a weekly performance of -1.66% finishing the day at $1.78, a loss of -7.77%.
Company Shares of Neuralstem, Inc. Drops by -13.33%
Neuralstem, Inc. (NYSEMKT:CUR) has lost 13.33% during the past week and dropped 7.14% in the last 4 weeks. The shares are however, negative as compared to the S&P 500 for the past week with a loss of 13.33%.